DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages
Author: Anoma Ranaweera, Medical Writer, Auckland, New Zealand. DermNet Editor in Chief: Adjunct A/Prof Dr Amanda Oakley, Dermatologist, Hamilton, New Zealand. Copy edited by Gus Mitchell/Maria McGivern. November 2018.
Cemiplimab (also called cemiplimab-rwlc; trade name Libtayo®; Regeneron Pharmaceuticals Inc., New York, USA) is a monoclonal antibody used for patients with advanced cutaneous squamous cell carcinoma (SCC).
Cemiplimab was approved by the US Food and Drug Administration (FDA) for patients with metastatic cutaneous SCC or locally advanced cutaneous SCC who are not candidates for curative surgery or curative radiation.
Cemiplimab was evaluated by the FDA under priority review, which is reserved for medicines that represent significant improvements in safety or efficacy in treating serious conditions.
Cemiplimab is the first and only treatment specifically approved and available for advanced cutaneous SCC in the US. Regeneron and Sanofi-Aventis (New Jersey, USA) will market cemiplimab jointly in the US. Cemiplimab belongs to a class of agents known as immune checkpoint inhibitors, that work by strengthening the body’s immune response to tumours.
In April 2018, the European Medicines Agency (EMA) accepted for review the marketing authorization application for cemiplimab for the treatment of patients with metastatic cutaneous SCC or with locally advanced SCC who are not candidates for surgery.
The EMA review process is anticipated to be complete by the first half of 2019. There are currently no EMA-approved treatments for advanced cutaneous SCC. Regulatory applications in additional countries are also currently being considered for submission.
Cemiplimab is currently unavailable in New Zealand.
The FDA approval of cemiplimab was based on a combined analysis of data from an open-label, multicentre, non-randomised Phase II trial known as EMPOWER-CSCC-1 (Study 1540) and two advanced cutaneous SCC expansion cohorts from a multicentre, open-label, non-randomised Phase I trial (Study 1423). Together, these trials represented the largest prospective data set in advanced cutaneous SCC.
The major efficacy outcome measures for EMPOWER-CSCC-1 and the two cutaneous SCC expansion cohorts were confirmed objective response rate (ORR) as assessed by an independent central review (ICR) and ICR-assessed duration of response.
For patients with metastatic cutaneous SCC without externally visible target lesions, ORR was determined by Response Evaluation Criteria in Solid Tumors (RECIST 1.1). For patients with externally visible target lesions (locally advanced and metastatic cutaneous SCC), ORR was determined by a composite endpoint that integrated ICR assessments of radiological data (RECIST 1.1) and digital medical photography (World Health Organisation criteria).
The efficacy analysis was conducted when all patients had the opportunity for at least 6 months of follow-up.
Patients received cemiplimab 3 mg/kg intravenously every 2 weeks for up to 48 weeks in Study 1423 or up to 96 weeks in Study 1540. Treatment continued until progression of the disease, unacceptable toxicity, or completion of planned treatment. Tumour response assessments were performed every 8 weeks.
Both studies excluded patients with:
Combined efficacy results (n = 108) from EMPOWER-CSCC-1 and the two advanced cutaneous SCC expansion cohorts from the Phase 1 trial are summarised in the table below:
|Efficacy Endpoints*||Metastatic CSCC (n =75)||Locally Advanced CSCC (n=33)||Combined CSCC (n=108)|
|Confirmed objective response (ORR)|
|ORR (95% confidence interval [CI])||47%
|Complete response rate†||5%||0%||4%|
|Partial response rate||41%||49%||44%|
|Duration of response (DOR)|
|Range in months||3–15+||1–13+||1–15+|
|Patients with DOR > 6 months, n (%)||21 (60%)||10 (63%)||31 (61%)|
* Median duration of follow-up: metastatic CSCC: 8.1 months; locally advanced CSCC: 10.2 months; combined CSCC: 8.9 months
†Includes patients with complete healing of prior cutaneous involvement; locally advanced CSCC patients in EMPOWER-CSCC-1 required biopsy to confirm complete response.
For the combined safety analysis (n = 163) of EMPOWER-CSCC-1 and the two advanced cutaneous SCC expansion cohorts, the most common adverse events reported were:
In 5% of patients, cemiplimab was discontinued permanently due to the following adverse events:
Serious adverse reactions occurred in 28% of patients. SAEs that occurred in at least 2% of patients were:
Adverse reactions that occured in less than 10% of patients with advanced cutaneous SCC receiving cemiplimab in Study 1423 and Study 1540 include:
The Grade 3 and 4 laboratory test abnormalities that worsened from baseline in fewer than 1% of patients with advanced cutaneous SCC who received cemiplimab in Study 1423 and Study 1540 are listed below.
If you are not based in New Zealand, we suggest you refer to your national drug approval agency for further information about medicines (eg, the Australian Therapeutic Goods Administration and the US Food and Drug Administration) or a national or state-approved formulary (eg, the New Zealand Formulary and New Zealand Formulary for Children and the British National Formulary and British National Formulary for Children).
© 2021 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.